Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-07-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司关于使用募集资金置换预先投入募投项目自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Changchun Baike Biotechnology Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects. It includes details about the fundraising, investment projects, approvals by the board and supervisory committee, independent director opinions, and audit reports. The document is relatively short (3805 characters) and primarily serves as a formal announcement of a financing and fund usage update rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. The content focuses on the company's capital management and compliance with regulatory requirements for the use of raised funds. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2021-07-12 Chinese
百克生物公司章程
Governance Information Classification · 95% confidence The document is a detailed draft of the company's Articles of Association (章程), covering chapters on general provisions, business scope, shares issuance and transfer, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, amendments, and other corporate governance matters. It includes detailed rules on shareholder rights, board and management roles, meeting procedures, and corporate governance structure. There is no financial data, earnings information, or audit report content. It is a governance document outlining the internal rules and structure of the company. Therefore, it fits the category of Governance Information (CGR).
2021-06-23 Chinese
百克生物首次公开发行股票科创板上市公告书
Regulatory Filings Classification · 95% confidence The document is titled as a "首次公开发行股票科创板上市公告书" which translates to "Initial Public Offering (IPO) Listing Announcement on the Science and Technology Innovation Board." It contains detailed information about the company's IPO, stock issuance, listing date, shareholder structure, risk factors related to the IPO, and regulatory approvals from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document is lengthy (15,000 characters) and provides comprehensive details about the IPO process, company background, shareholder information, and stock listing specifics. It is not a financial report like an annual or quarterly report, nor is it a simple announcement of a report. It is a formal listing announcement document related to the company's IPO and stock market listing. This type of document fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about the IPO and listing, not a financial report or earnings release.
2021-06-23 Chinese
百克生物关联交易的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction involving Changchun Baike Biotechnology Co., Ltd. and its controlling shareholder Changchun High-tech Industry Group Co., Ltd. It discusses the planned licensing cooperation agreement for COVID-19 vaccine technology, including transaction terms, risk disclosures, approval procedures, and independent opinions. The document is a formal announcement of a related-party transaction, not a financial report, earnings release, or management discussion. It does not contain financial statements or quarterly results but focuses on the disclosure of a significant related-party transaction and its terms. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about a related-party transaction and does not fit other more specific categories like Capital/Financing Update or Board/Management Information. The document length (6564 characters) and content confirm it is a full announcement, not a brief notice or report publication announcement.
2021-06-21 Chinese
百克生物首次公开发行股票并在科创板上市发行结果公告
Capital/Financing Update Classification · 100% confidence The document is titled as an "发行结果公告" which translates to "Issuance Results Announcement" for the company's initial public offering (IPO) and listing on the STAR Market (科创板). It details the issuance price, number of shares issued, strategic placement, online and offline subscription results, allotment, and underwriting details. It includes extensive data on share allocations, subscription amounts, and lock-up periods. The document is an official announcement of the results of a capital raising event (IPO). It is not a financial report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. It is clearly an update on the company's capital raising and share issuance activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication announcement but a full issuance result announcement.
2021-06-20 Chinese
百克生物首次公开发行股票并在科创板上市招股说明书
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for the initial public offering (IPO) and listing of Changchun BCHT Biotechnology Co. on the Shanghai Stock Exchange STAR Market (科创板). It includes extensive information about the company's business, risk factors, financial data, governance, and the offering details. The document is titled as a 招股说明书 (Prospectus), which is a formal disclosure document used in IPOs to provide comprehensive information to potential investors. It is not an annual report, earnings release, or any other type of periodic financial report. It is also not a brief announcement or a certification document. The length and content confirm it is the actual IPO prospectus document, which falls under the category of Capital/Financing Update (CAP) as it relates to the company's fundraising and capital market activities through the IPO process.
2021-06-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.